96 related articles for article (PubMed ID: 28199812)
1. Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
Ludvigsson J; Wahlberg J; Casas R
N Engl J Med; 2017 Feb; 376(7):697-699. PubMed ID: 28199812
[No Abstract] [Full Text] [Related]
2. Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route.
Ludvigsson J
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111075
[TBL] [Abstract][Full Text] [Related]
3. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Front Immunol; 2020; 11():564921. PubMed ID: 33162978
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Ludvigsson J; Sumnik Z; Pelikanova T; Nattero Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Katsarou A; Hanas R; Hernandez C; Clemente León M; Gómez-Gila A; Lind M; Lozano MF; Sas T; Samuelsson U; Pruhova S; Dietrich F; Puente Marin S; Nordlund A; Hannelius U; Casas R
Diabetes Care; 2021 Jul; 44(7):1604-1612. PubMed ID: 34021020
[TBL] [Abstract][Full Text] [Related]
5. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
Ludvigsson J; Tavira B; Casas R
N Engl J Med; 2017 Jul; 377(4):403-5. PubMed ID: 28745988
[No Abstract] [Full Text] [Related]
6. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
Haller M; Atkinson M; Schatz D
N Engl J Med; 2017 Jul; 377(4):403. PubMed ID: 28748691
[No Abstract] [Full Text] [Related]
7. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
[TBL] [Abstract][Full Text] [Related]
8. Glutamic Acid decarboxylase therapy for recent-onset type 1 diabetes: are we at the end or the beginning of finding a cure?
Fleming GA; Klonoff DC
J Diabetes Sci Technol; 2009 Mar; 3(2):215-8. PubMed ID: 20144352
[No Abstract] [Full Text] [Related]
9. Disease prevention with islet autoantigens.
Eisenbarth GS; Jasinski JM
Endocrinol Metab Clin North Am; 2004 Mar; 33(1):59-73, viii. PubMed ID: 15053895
[No Abstract] [Full Text] [Related]
10. Glutamic acid decarboxylase immunotherapy for type 1 diabetes.
Ludvigsson J
Curr Opin Endocrinol Diabetes Obes; 2022 Aug; 29(4):361-369. PubMed ID: 35776501
[TBL] [Abstract][Full Text] [Related]
11. Administering 25-hydroxyvitamin D3 in vitamin D-deficient young type 1A diabetic patients reduces reactivity against islet autoantigens.
Federico G; Focosi D; Marchi B; Randazzo E; De Donno M; Vierucci F; Bugliani M; Campi F; Scatena F; Saggese G; Mathieu C; Marchetti P
Clin Nutr; 2014 Dec; 33(6):1153-6. PubMed ID: 24461876
[TBL] [Abstract][Full Text] [Related]
12. Arresting type 1 diabetes after diagnosis: GAD is not enough.
Mathieu C; Gillard P
Lancet; 2011 Jul; 378(9788):291-2. PubMed ID: 21715000
[No Abstract] [Full Text] [Related]
13. Administering glutamic acid decarboxylase to NOD mice prevents diabetes.
Tisch R; Yang XD; Liblau RS; McDevitt HO
J Autoimmun; 1994 Dec; 7(6):845-50. PubMed ID: 7888040
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D in diabetes mellitus-a new field of knowledge poised for D-velopment.
Alfonso B; Liao E; Busta A; Poretsky L
Diabetes Metab Res Rev; 2009 Jul; 25(5):417-9. PubMed ID: 19565622
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of zinc transporter 8 antibodies in gestational diabetes mellitus.
Dereke J; Nilsson C; Landin-Olsson M; Hillman M
Diabet Med; 2012 Dec; 29(12):e436-9. PubMed ID: 22924602
[TBL] [Abstract][Full Text] [Related]
16. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
17. Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.
Treiber G; Prietl B; Fröhlich-Reiterer E; Lechner E; Ribitsch A; Fritsch M; Rami-Merhar B; Steigleder-Schweiger C; Graninger W; Borkenstein M; Pieber TR
Clin Immunol; 2015 Dec; 161(2):217-24. PubMed ID: 26277548
[TBL] [Abstract][Full Text] [Related]
18. [C-peptide as the decisive factor for classification of type 1 diabetes mellitus and type 2 diabetes mellitus].
Perusicová J; Bárová H; Hill M; Masek Z
Vnitr Lek; 2002 Jun; 48(6):490-9. PubMed ID: 12132349
[TBL] [Abstract][Full Text] [Related]
19. [Vaccination against type 1 diabetes at the clinical trial stage].
Lernmark A
Lakartidningen; 1999 Mar; 96(11):1300-2. PubMed ID: 10194908
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study.
Brekke HK; Ludvigsson J
Pediatr Diabetes; 2007 Feb; 8(1):11-4. PubMed ID: 17341286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
